Discovery - University of Dundee - Online Publications

Library & Learning Centre

Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder

Standard

Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder : complementary treatment options. / Hodgkins, Paul; Shaw, Monica; Coghill, David; Hechtman, Lily; Coghill, David.

In: European Child & Adolescent Psychiatry, Vol. 21, No. 9, 2012, p. 477-492.

Research output: Contribution to journalScientific review

Harvard

Hodgkins, P, Shaw, M, Coghill, D, Hechtman, L & Coghill, D 2012, 'Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options' European Child & Adolescent Psychiatry, vol 21, no. 9, pp. 477-492.

APA

Hodgkins, P., Shaw, M., Coghill, D., Hechtman, L., & Coghill, D. (2012). Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. European Child & Adolescent Psychiatry, 21(9), 477-492doi: 10.1007/s00787-012-0286-5

Vancouver

Hodgkins P, Shaw M, Coghill D, Hechtman L, Coghill D. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. European Child & Adolescent Psychiatry. 2012;21(9):477-492.

Author

Hodgkins, Paul; Shaw, Monica; Coghill, David; Hechtman, Lily; Coghill, David / Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder : complementary treatment options.

In: European Child & Adolescent Psychiatry, Vol. 21, No. 9, 2012, p. 477-492.

Research output: Contribution to journalScientific review

Bibtex - Download

@article{db5c27d8dc8c43299f47111808f9b92f,
title = "Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder",
author = "Paul Hodgkins and Monica Shaw and David Coghill and Lily Hechtman and David Coghill",
year = "2012",
volume = "21",
number = "9",
pages = "477--492",
journal = "European Child & Adolescent Psychiatry",
issn = "1018-8827",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder

T2 - complementary treatment options

A1 - Hodgkins,Paul

A1 - Shaw,Monica

A1 - Coghill,David

A1 - Hechtman,Lily

AU - Hodgkins,Paul

AU - Shaw,Monica

AU - Coghill,David

AU - Hechtman,Lily

PY - 2012

Y1 - 2012

N2 - Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders among school-aged children. It is highly symptomatic and associated with significant impairment. This review examines the role of stimulant medications in the treatment of children and adolescents with ADHD. Published clinical studies that compared methylphenidate- and amfetamine-based stimulants in children and adolescents with ADHD support the therapeutic utility of stimulant treatments, and suggest robust efficacy and acceptable safety outcomes in groups treated with either stimulant. Evidence-based guidelines agree that each patient with ADHD is unique and individual treatment strategies that incorporate both drug and non-drug treatment options should be sought. In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy.

AB - Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders among school-aged children. It is highly symptomatic and associated with significant impairment. This review examines the role of stimulant medications in the treatment of children and adolescents with ADHD. Published clinical studies that compared methylphenidate- and amfetamine-based stimulants in children and adolescents with ADHD support the therapeutic utility of stimulant treatments, and suggest robust efficacy and acceptable safety outcomes in groups treated with either stimulant. Evidence-based guidelines agree that each patient with ADHD is unique and individual treatment strategies that incorporate both drug and non-drug treatment options should be sought. In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy.

U2 - 10.1007/s00787-012-0286-5

DO - 10.1007/s00787-012-0286-5

M1 - Scientific review

JO - European Child & Adolescent Psychiatry

JF - European Child & Adolescent Psychiatry

SN - 1018-8827

IS - 9

VL - 21

SP - 477

EP - 492

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy